Zacks Research Issues Positive Estimate for Neogen Earnings

Neogen Co. (NASDAQ:NEOG) – Equities researchers at Zacks Research boosted their Q4 2025 earnings per share estimates for Neogen in a research report issued to clients and investors on Tuesday, December 3rd. Zacks Research analyst R. Department now forecasts that the company will earn $0.18 per share for the quarter, up from their prior estimate of $0.17. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.61 EPS and FY2027 earnings at $0.75 EPS.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings results on Thursday, October 10th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Neogen had a negative net margin of 2.58% and a positive return on equity of 2.80%. The firm had revenue of $217.00 million for the quarter, compared to the consensus estimate of $215.05 million. During the same period in the previous year, the company posted $0.11 earnings per share. Neogen’s quarterly revenue was down 5.2% on a year-over-year basis.

Separately, StockNews.com raised Neogen to a “sell” rating in a research note on Monday, September 30th.

Neogen Price Performance

NASDAQ:NEOG opened at $12.37 on Thursday. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -112.45 and a beta of 1.21. Neogen has a 1 year low of $11.46 and a 1 year high of $20.89. The business has a 50 day simple moving average of $14.75 and a 200-day simple moving average of $15.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.41 and a quick ratio of 2.79.

Insider Activity

In other Neogen news, CEO John Edward Adent purchased 14,500 shares of Neogen stock in a transaction dated Friday, October 11th. The shares were purchased at an average cost of $13.80 per share, for a total transaction of $200,100.00. Following the completion of the acquisition, the chief executive officer now owns 216,477 shares in the company, valued at $2,987,382.60. This represents a 7.18 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On Neogen

Several hedge funds and other institutional investors have recently modified their holdings of the business. Inspire Investing LLC raised its holdings in shares of Neogen by 2.7% in the second quarter. Inspire Investing LLC now owns 26,074 shares of the company’s stock worth $408,000 after buying an additional 685 shares during the period. Stephens Inc. AR increased its holdings in Neogen by 2.6% during the 3rd quarter. Stephens Inc. AR now owns 35,930 shares of the company’s stock worth $604,000 after purchasing an additional 909 shares during the period. Arizona State Retirement System increased its holdings in Neogen by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 57,609 shares of the company’s stock worth $900,000 after purchasing an additional 1,079 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Neogen by 142.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in Neogen by 3.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 36,630 shares of the company’s stock worth $573,000 after purchasing an additional 1,190 shares during the period. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.